clinical trial · NCT06903338
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Viral HepatitisTobevibartElebsiran
brief summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
started
Mar 12, 2025
primary completion
Dec 31, 2026
completion
May 1, 2031
last updated
Apr 8, 2026
official title
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol